<SEC-DOCUMENT>0001213900-20-033377.txt : 20201027
<SEC-HEADER>0001213900-20-033377.hdr.sgml : 20201027
<ACCEPTANCE-DATETIME>20201027080331
ACCESSION NUMBER:		0001213900-20-033377
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201027
FILED AS OF DATE:		20201027
DATE AS OF CHANGE:		20201027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		201262089

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea128966-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
6-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of: October 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-36578</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><U>ENLIVEX
THERAPEUTICS LTD.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>14
Einstein Street, Nes Ziona, Israel 7403618</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2020, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, issued a press release
announcing that it will host a COVID-19 webinar on Thursday, November 5, 2020, at 10:00 a.m. Eastern Time. A copy of such press
release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    <BR>
No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="ea128966ex99-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Press Release issued by Enlivex Therapeutics Ltd. on October 27, 2020.</U></FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
    Therapeutics Ltd.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oren Hershkovitz</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
    Hershkovitz<BR>
    Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
October 27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea128966ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON OCTOBER 27, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 12pt">Enlivex to Host COVID-19 Webinar:
The Staging of a New Disease and Its Implications for Treatment Options, with Mount Sinai Key Opinion Leader</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*
Findings and Analyses On 68,000 COVID-19 Patients Discussed in the Webinar on Thursday, November 5<SUP>th</SUP> @ 10amET *</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nes
Ziona, Israel, October 27, 2020 (GLOBE NEWSWIRE) --&nbsp;</B>Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;),
a clinical-stage immunotherapy company, today announced that it will host a Key Opinion Leader (KOL) webinar on COVID-19 and its
implications for treatment options on Thursday, November 5, 2020 at 10am Eastern Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
webinar will feature a presentation by KOL Carlos Cordon-Cardo, MD, PhD, from Mount Sinai hospital, who will discuss his team&rsquo;s
findings in more than 68,000 COVID-19 patients, including more than 100 autopsies, a proposed framework for optimized treatment
options for treating COVID-19 patients in severe and critical condition, and a short discussion regarding Allocetra&trade; by
Enlivex as a product candidate for consideration. Dr. Cordon-Cardo with be available to answer questions following the formal
presentations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex's
management team will discuss the recently reported positive top-line results of a Phase Ib investigator-initiated clinical trial
of Allocetra&trade; in five COVID-19 patients in severe and critical condition, and the on-going Phase II investigator-initiated
clinical trial, which is expected to recruit up to twenty-four COVID-19 patients in severe or critical condition. The clinical
trial has been designed to assess Allocetra&trade; in combination with standard of care treatment, and plans to evaluate safety,
tolerability, cytokine profile and efficacy parameters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
register for the webinar, please click here.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
recently reported positive top-line results of a previously announced Phase Ib investigator-initiated clinical trial of Allocetra&trade;<SUP>
</SUP>&nbsp;in COVID-19 patients in severe and critical condition in Hadassah Hospital, one of the largest hospitals in Israel.
The Phase Ib clinical trial included five COVID-19 patients, three in severe condition and two in critical condition. All five
patients completely recovered from their respective severe/critical condition and were released from the hospital after an average
of 5 days (severe) and 9 days (critical), following administration of Allocetra&trade;, at which time they were all COVID-19 PCR
negative. There were no reported severe adverse events relating to the administration of Allocetra&trade;<SUP> </SUP> in the patients,
and the therapy was well-tolerated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
THE ALLOCETRA COVID-19 PHASE II CLINICAL TRIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 study is a multi-center investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to twenty-four
COVID-19 patients in severe or critical condition, as defined by the U.S. National Institute of Health (NIH), and is designed
to assess Allocetra&trade;<SUP>
</SUP> in combination with standard of care treatment. Safety, tolerability, cytokine profile and efficacy
parameters are planned to be evaluated. Up to twenty-four patients are expected to be recruited, subject to each patient&rsquo;s
eligibility and signing of an informed consent to participate and receive treatment. Eligibility criteria include an existing
illness with at least one of (a) radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or (b) Sp/O2 ratio lower or
equal to 94% on room air, or (c) requiring supplemental oxygen (low flow or high flow), with a P/F ratio of below 350 but higher
than 150. Exclusion criteria include (a) pregnancy, lactation and childbearing potential woman who are not willing to use acceptable
contraceptives measures for the entire study duration, (b) Illness combined with other organ failure requiring organ support other
than a respirator, including Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration
rate (eGFR) &lt; 30), (c) intubated patients (due to inability to sign an informed consent), (d) patients with malignant tumor,
other serious systemic diseases and psychosis, (e) patients who are participating in other clinical trials or treated with any
experimental agents that may contradict this trial, (f) co-infection of HIV or tuberculosis, (g) known immunocompromised state
or medications known to be immunosuppressive, and (h) patients with P/F ratio or S/F ratio of &lt;150 or a change in status of
eligibility manifested by a rapid decline of P/F ratio between eligibility status and actual drug delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ENLIVEX</B><BR>
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune
system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression
of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and
COVID-19, as well as enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, visit&nbsp;http://www.enlivex.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Safe Harbor Statement:&nbsp; This press release contains
forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo;,
&ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo;
and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results
of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA&trade;<SUP>
</SUP>&nbsp;programs.
All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex&rsquo;s
business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial
products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate
data that would support the approval or marketing of these products for the indications being studied or for other indications;
that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results
to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce
results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials
may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA&trade;<SUP>
</SUP>&nbsp;product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing
issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation,
the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and
other third parties.&nbsp; In addition to the risk factors described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in Enlivex&rsquo;s filings with the Securities and Exchange Commission,
including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp;
The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ENLIVEX CONTACT<BR>
Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR RELATIONS CONTACT</B><BR>
Eric Ribner<BR>
LifeSci Advisors<BR>
eric@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 / # 2(  A$! Q$!_\0
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M!I0PMSKETU_..YC7[OX?ZLU8T.PE\<?!<:/ #)?:-JT?E@<D0S-C\LNQ_P"
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MQO)(5@CEMP+\6;_O-Y93GYN1P>#[<U3EUZ[E8,([:-O.6X=HXL&21<X9OS/
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
